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2High YKL-40 is associated with poor survival in patients with
renal cell carcinoma: novel independent prognostic marker
Abstract
Objective: YKL-40 is an inflammation-associated glycoprotein supposed to have
a role in cell survival and angiogenesis. RCC is characterized by varying
prognosis and risk of relapse after disease free time of years. Prognostic markers
are critically needed. We investigated if YKL-40 could serve as a useful
biomarker in RCC patients. Materials and Methods: Blood samples from 82
patients with RCC were collected at the time of diagnosis and 3, 5, and 9 months
and 2 and 3 years after nephrectomy. Levels of YKL-40 were determined by
ELISA. Survival of patients and relapse of RCC was followed up to 15 years.
Results: Circulating YKL-40 levels were increased in patients with metastatic
RCC at the time of diagnosis (115.7, 61.0-221.6 ng/ml; median, IQR). More
importantly, among patients primarily diagnosed to have nonmetastatic RCC,
baseline YKL-40 levels were significantly higher in those patients who
experienced a relapse during the follow-up (103.7, 59.3-242.0 ng/ml) than in
patients without relapse (50.6, 33.8-97.1 ng/ml). Moreover, high baseline YKL-
40 was highly associated with poor prognosis in RCC: in age-adjusted univariate
analysis, YKL-40 over 120 ng/ml (highest tertile) predicted over 5-fold mortality
in 5 years, and in multivariate analysis high YKL-40 stayed as a statistically
significant independent risk factor for 5 and 15 years survival. Conclusions:
Increased circulating YKL-40 levels were found to be significantly associated
with poor survival in patients with RCC. The results suggest YKL-40 as a useful
novel biomarker in evaluating prognosis and relapse risk in RCC, being
especially beneficial in patients primarily diagnosed to have nonmetastatic RCC.
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3Introduction
Renal cell carcinoma (RCC) belongs to the ten most common malignancies worldwide
and for unrevealed reasons, it is more common in men and in developed countries.
Clear cell carcinoma is the prevailing subtype of RCC, the other subtypes including
papillary, cromophope and ductal carcinomas. The prognosis of RCC is variable and
depends on the size of the primary tumor and the dissemination at the time of diagnosis:
5-year survival of patients with local tumor with diameter under 7 cm may be 80 – 95
%, whereas the 5-year survival of patients with stage IV RCC has been reported to be
less than 10 % before the development of the latest targeted drugs. Today many of the
RCCs are found incidentally, when imaging is used to investigate other abdominal
complaints. In patients with RCC who don’t have any evidence of metastases, partial or
radical nephrectomy is the treatment of choice with curative intent. However, a fourth
of these patients develop later recurrence or metastases [1].
In recent years, several genetic factors associated with RCC have been
recognized, e.g. mutation in von Hippel-Lindau tumor suppressor gene resulting in
changes in the response to hypoxia and further, activation of genes associated with
angiogenesis, cell migration, and metabolism. The primary treatment of RCC is surgery.
Systemic drugs such as cytokines interleukin-2 and interferon-α, vascular endothelial
growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR)
inhibitors are used to treat metastatic RCC [1]. In addition, check-point inhibitors alone
or in combinations have been shown promise in the most recent clinical trials [2,3].
YKL-40, known also by names human cartilage glycoprotein-39 (HcGP-39),
Chitinase 3-like 1 (Chi3-l1), and breast regression protein 39 (BRP-39), is an
enzymatically inactive glycoprotein belonging to the 18-glycosyl hydrolase family. In
4addition to its relation to inflammation, YKL-40 is known as a factor potentially
associated with malignancies [4].
It is a clinical challenge to estimate patients’ prognosis after radical primary
treatment of RCC. Novel prognostic tools are needed to identify patients with high-risk
characteristics and to develop strategies for follow-up of this increasing patient group
[1]. The most powerful known independent prognostic factors are clinical stage and
histological grade even though candidates for prognostic and predictive factors have
been actively investigated [1,5]. The aim of the present study was to investigate if
serum levels of YKL-40 are associated with the prognosis of renal cell carcinoma.
5Materials and methods
Patients
The present study included 82 patients with renal cell carcinoma diagnosed in Tampere
University Hospital, Tampere, Finland. The patients were treated with a radical or
palliative nephrectomy and patients with metastatic disease received oncologic
treatment. Thereafter, the patients were followed up at the university clinic according to
a following schedule: 3, 9 and 15 months and at 2, 3, 4 and 5 years. After 5 years,
follow-up was continued by general practitioners at patient’s hometown. Individual
survival status (date of death, cause of death) and clinical diagnoses were collected from
the patient’s records up to 15 years. Endpoints were relapse (reappearance of a sign of
the disease after radical surgery; this was applied for the tumours primarily diagnosed as
nonmetastatic, i.e. N0M0) and disease-specific survival (death due to RCC) [6].
The 1997 TNM-classification was used to describe RCC [7]. T1-T2/N0M0 was
regarded as local, T3-T4/N0M0 as advanced and N+ and/or M+ as metastatic disease.
The present patient cohort did not include any T4N0M0 tumours; all cases classified as
advanced tumours were T3N0M0. Histology of tumors was classified according to the
Heidelberg classification [8] and graded according to the WHO classification [9]. For
the statistical analysis, the TNM classification was dichotomized according to the
metastatic status as nonmetastatic (N0M0) or metastatic (N+ and/or M+) and also the
grade of the tumor was dichotomized to grades 1-2 and grade 3.
Blood samples and measurement of YKL-40
Blood samples were collected at baseline and postoperatively at 3, 9 and 15 months, and
2 and 3 years. Serum samples were stored at -80 °C until analyzed. YKL-40 was
6measured with enzyme-linked immunosorbent assay (ELISA) using commercial
reagents (R&D systems Europe ltd, Abingdon, UK, DuoSet ELISA) according to the
manufacturer’s instructions.
Statistics
Differences in demographics between RCC groups (nonmetastatic without or with
relapse and metastatic) were analyzed by Pearson Chi-Square test or independent
samples Kruskall-Wallis test when appropriate. Changes in YKL-40 levels before and
after nephrectomy were studied by Related-Samples Wilcoxon Signed Rank Test.
Changes in YKL-40 values according to nonmetastatic RCC with or without relapse
during 3 years’ follow-up were analyzed by Related samples Friedman's Two-Way
Analysis of Variance by Ranks. Differences in baseline YKL-40-values between RCC-
groups were calculated by Mann-Whiney test. Due to the skew distribution, the
logaritmic transformation (Ln) was performed to normalize the distribution of YKL-40
for the further analyses. Transformed YKL-40 was used to model the effect of
increasing YKL-40 values on RCC-survival. YKL-40 values were categorized for
tertiles producing classes ≤55.0, 55.1-120.0 and >120.0 ng/ml. Those YKL-40 tertiles
were used together with age, gender, metastatic status and grade to model age-adjusted
univariate and multivariate 5- and 15-year survival. Survival analyses were performed
using Cox proportional hazard regression models showing results by hazard ratios with
95 % confidence intervals. Survival times were illustrated by Kaplan-Meier curves with
log-rank analyses by Mantel-Cox to test the equality of the survival distributions. All
data was analyzed using IBM SPSS Statistics version 23 (IBM SPSS Statistics, IBM
Corporation, Chicago, IL). P-values below 0.05 were considered as statistically
7significant.
Results
Demographics of the patients and key variables of the cancer are presented in Table 1.
At the time of diagnosis 37 patients were found to have local disease (T1-T2/N0M0), 24
patients had advanced disease (T3/N0M0), whereas 21 patients had metastatic RCC (N+
and/or M+). For the further analyses the TNM classification was dichotomized to
nonmetastatic (N0M0) and metastatic (N+ and/or M+) disease. During the follow-up,
RCC relapsed in 31 patients, who had primarily diagnosed to have a nonmetastatic (T1-
T3) disease and treated with radical surgery. Forty-six patients died within the 15 years’
follow-up, 30 of them during the first 5 years.
At the time of diagnosis, the median serum YKL-40 level was 90.9 ng/ml (IQR
41.8 – 182.0 ng/ml). YKL-40 levels were significantly higher in patients with the
metastatic RCC (115.7; 61.0 – 221.6 ng/ml, n=21, p=0.006) and in nonmetastatic
patients with relapsing disease (103.7; 59.3 – 242.0 ng/ml, n=31, p = 0.005) than in
those with nonmetastatic RCC without relapse during the follow-up (50.6; 33.8 – 97.1
ng/ml, n=30) (Figure 1).
When YKL-40 levels were compared before and after the nephrectomy, no
statistically significant change was seen in the whole group or in any of the three
subgroups of the patients (Table 2). In the patients with nonmetastatic disease at the
baseline, the complete series of blood samples from baseline to 3 years was available
from 18 patients. There was no significant change in YKL-40 levels during this 3 years’
follow-up (Table 3).
8When the association of the circulating YKL-40 with the survival was
investigated, the baseline YKL-40 was found to predict mortality. In the whole study
population, one unit increase in the log-transformed YKL-40 increased 5-year and 15-
year mortality over 80 % (5 year: HR 1.84, 95% CI 1.27 – 2.67, p = 0.001; 15-year: HR
1.85, 95% CI 1.37 – 2.51, p < 0.001). The association was even stronger in patients with
metastatic RCC: one unit increase in log-transformed YKL-40 increased 5 and 15-year
mortality 3-fold (5 year: HR 3.31, 95% CI 1.63 – 6.71, p = 0.001; 15-year: HR 2.98,
95% CI 1.51 – 5.85, p = 0.002). In support, in patients with metastatic disease, baseline
YKL-40 correlated negatively with survival time after the surgery (Spearman’s rho =
-0.608, p = 0.003, n=21).
To further assess the association of YKL-40 with survival, the patients were
divided into tertiles according to baseline YKL-40 levels: lowest tertile, YKL-40 < 55
ng /ml (n = 27), medium tertile, YKL-40 = 55-120 ng/ml (n=27), and highest tertile
YKL-40 >120 ng/ml (n = 28). The cumulative survival between YKL-40 levels differed
significantly both for 5-year survival (log-rank (Mantel-Cox) p = 0.008) and for 15-year
survival (p<0.001) (Figure 2).
Moreover, in age-adjusted univariate analysis, baseline YKL-40 over 120 ng/ml
(highest tertile) predicted over 5-fold mortality during 5 years period (HR 5.26, 95% CI
1.67 – 16.59, p = 0.005) and over 4-fold during 15 years (HR 4.34, 95% CI 1.87 –
10.07, p = 0.001) as compared to the lowest tertile (YKL-40 < 55 ng/ml). When the risk
factors for mortality in patients with renal cell carcinoma were assessed, metastatic
status (metastatic vs. nonmetastatic tumour at the time of diagnosis), tumor grade (3 vs.
1-2), and high YKL-40 (the highest tertile) were all significant risk factors for 5 and 15-
year mortality. In multivariate analysis, high YKL-40 (> 120 ng/ml) stayed as a
9statistically significant independent risk factor for both 5-year and 15-year survival
(Table 4).
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Discussion
In the present study, YKL-40 was shown to associate with the prognosis of renal cell
carcinoma. Increased levels of circulating YKL-40 were found in patients with
metastatic RCC at the time of diagnosis. Importantly, in patients whose disease
appeared as nonmetastatic at the time of diagnosis and primary surgical treatment,
baseline YKL-40 was found to be higher in those patients who subsequently
experienced a relapse. High YKL-40 levels were significantly associated with poor
survival; the strongest association being present in patients with metastatic RCC.
YKL-40, a glycoprotein with a molecular weight of approximately 40 kDa, is a
member of a protein family of 18-glycosyl hydrolases and in contrast to the true
chitinases of this protein family, YKL-40 is enzymatically inactive [10]. However, two
distinct binding sites for oligosaccharides are recognized [11]. The CHI3L1-gene
coding YKL-40 protein is localized to chromosome 1 and its full amino acid sequence
has been reported [12].
The circulating levels of YKL-40 in patients with RCC detected in the present
study were higher than those in healthy people or in patients with other diseases
measured in our laboratory recently [13-15]. Increased levels of YKL-40 have been
associated with diseases characterized by acute or chronic inflammation and also with
cancer [4]. The detailed role of YKL-40 in malignant diseases is not known but some
effects have been proposed: YKL-40 could act as a proinflammatory, antiapoptotic, or
growth-promoting factor, or be involved in angiogenesis or in the extracellular matrix
remodeling [16].
There are only a few previous studies evaluating YKL-40 in RCC. Zhang et al.
studied YKL-40 expression in RCC tumors by immunohistochemical staining and
found an intense staining of intracellular YKL-40 to associate with poor prognosis [17].
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Berntsen and coworkers reported serum YKL-40 to associate with poor prognosis in
patients with metastatic RCC treated with experimental dendritic cell vaccination
therapy; YKL-40 levels increased significantly within the first four weeks of the
treatment, with higher increase being in patients with progressive disease [18].
Although the number of the patients in the present study is limited there are several
strengths. In addition to patients with metastatic disease, patients with a nonmetastatic
RCC were included, the treatment was similar for all patients, the study design was
longitudinal and patients were followed up to 15 years after the diagnosis. The findings
of the present study are also supported by previous studies in other solid malignancies.
High circulating levels of YKL-40 have been found to be associated with poor
prognosis also in patients with breast cancer, gynecological carcinomas, bladder cancer,
colorectal cancer, and hepatocellular carcinoma [16,19-22].
YKL-40 is expressed in a variety of cell types including inflammatory and
malignant cells e.g. macrophages, neutrophils, osteosarcoma-, and glioblastoma cells
[4]. The results of the present study, however, indicate that tumor cells were not the
primary source of the circulating YKL-40 as the levels remained high despite the
surgical removal of the tumor. Unchanged YKL-40 levels after nephrectomy rule out
also the possibility that kidney function could significantly account for increased YKL-
40 levels, as the operation is known to decrease glomerular filtration rate [23]. These
views are supported by a recent study of vom Dorp et al, who found increased YKL-40
expression in peritumoral renal tissue and YKL-40 positive tumor tissue in some cases,
but there was no correlation between circulating YKL-40 and its tissue levels or
creatinine [24].
RCC tumors are associated with large amount of tumor-associated macrophages
(TAMs) with a mixed M1/M2 phenotype [25]. Macrophages have different roles in
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tumorigenesis depending on their phenotype. Classically activated M1 macrophages
have been linked to protective role against the tumor, while M2 macrophages seem to
have a tumour-supporting role [26]. Intriguingly, YKL-40 is acknowledged as a marker
of alternatively activated M2 macrophages, which have been shown to suppress
adaptive tumor-specific immune response and promote tumor growth, angiogenesis,
invasion, metastasis and stroma remodeling [26,27]. Further, YKL-40 seems to be a
pro-angiogenic factor itself as it has been shown to induce VEGF expression in U87
glioblastoma cells and angiogenesis in vitro and in vivo [27-29]. In the study by Faibish
et al. blocking YKL-40 with monoclonal antibody was demonstrated to suppress tumor
growth and angiogenesis [30]. In the present study, YKL-40 may have been produced
by M2 type TAMs in RCC patients, as was shown with small cell lung cancer cells
implanted in mice [31] and this could explain the association of YKL-40 with more
aggressively progressing tumors. In addition, breast cancer cells have been reported to
educate macrophages towards the M2 type phenotype, which correlates to recurrence
free survival even in early breast cancer [32]. High YKL-40 levels may even hold
potential as a biomarker for the disease type responding favorably to the treatment with
drugs inhibiting vascular endothelial growth factor (VEGF) pathway. Based on the
findings of the present study we cannot confirm these hypotheses, but the current results
do indeed support YKL-40 as a prognostic biomarker in RCC.
Classical biomarkers used in algorithms for evaluating the prognosis of RCC are
tumor node metastasis (TNM) and stage classifications, tumor size and necrosis,
performance status of the patient, and for metastatic disease also circulating calcium,
hemoglobin, lactate dehydrogenase, thrombocyte- and leucocyte counts [1]. In the
present study baseline YKL-40 predicted a relapse in patients, who had a nonmetastatic
disease at the time of diagnosis and primary surgical treatment. To our knowledge, this
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has not been reported previously. YKL-40 was also strongly associated with poor
survival, as only the metastatic status of the cancer had higher hazard ratio on 5 or 15-
years mortality. More importantly, in the multivariate analysis YKL-40 was found to be
as a statistically significant independent risk factor for poor survival in RCC. YKL-40
also correlated negatively with survival time in patients with metastatic RCC. There is a
lack of good biomarkers in RCC, and the present results propose YKL-40 as a novel
biomarker to be added into the repertoire when assessing probability of a relapse,
especially in a nonmetastatic disease, and risk of mortality in RCC.
The present results propose circulating YKL-40 as a useful prognostic
biomarker in RCC patients. The results encourage further confirming studies in larger
patient groups. Intriguing hypotheses in mechanisms of the role of YKL-40 in cancers
are discussed.
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Tables
Table 1. Demographics of the study population.
All
(n=82)
Nonmetastatic RCC Metastatic
RCC
(n=21)
pwithout relapse
(n=30)
with relapse
(n=31)
Age, Median (range) 67 (33 – 85) 63 (33 – 84) 71 (45 – 85) 65 (45 – 74) 0.028
Gender, n (%)
male 54 (66) 21 (70) 20 (65) 13 (62) 0.819
female 28 (34) 9 (30) 11 (35) 8 (38)
PAD, n (%)
Clear cell 73 (89) 27 (90) 27 (87.1) 19 (90.5)
Chromophobe 3 (3.7) 1 (3.3) 1 (3.2) 1 (4.8)
Papillary 5 (6.1) 2 (6.7) 3 (9.7) 0 (0)
Collecting duct 1 (1.2) 0 (0) 0 (0) 1 (4.8)
Stage, n (%)
Local
(T1-T2/N0M0) 37 (45) 22 (27) 15 (18)
Advanced
(T3-T4/N0M0)* 24 (29) 8 (10) 16 (19)
Metastatatic
(N+ and/or M+) 21 (26) 21 (26)
Grade, n (%)
1-2 54 (66) 23 (77) 20 (65) 11 (52) 0.194
3 28 (34) 7 (23) 11 (35) 10 (48)
5-year survival, n (%) 52 (63) 30 (100) 20 (65) 2 (9) <0.001
15-year survival, n (%) 36 (44) 30 (100) 5 (16) 1 (5) <0.001
The difference between groups were tested by independent samples Kruskall-Wallis test or Pearson Chi-
Square test.
*The present patient cohort did not include any T4N0M0 tumours; all cases classified as advanced tumours
were T3N0M0.
Table 2. Serum YKL-40 levels before and after surgical in patients with metastatic or nonmetastatic renal cell carcinoma with or without relapse
during a 15-years follow-up.
YKL-40 (ng/ml)
Baseline Post-surgery p
Md (IQR) Md (IQR)
All (n=61) 84.9 (38.0 – 172.3) 77.9 (39.4 – 144.4) 0.516
Metastatic (n=9) 91.4 (43.4 – 190.5) 63.0 (44.8 – 227.8) 0.594
Nonmetastatic with relapse (n=25) 103.7 (68.4 – 231.6) 110.0 (65.4 – 144.4) 0.427
Nonmetastatic without relapse (n= 27) 48.5 (31.1 – 90.8) 59.6 (31.1 – 154.5) 0.107
Md=Median; IQR=Interquartile range. Differences (p) between YKL-40 levels before and after nephrectomy were analyzed by
Related-Samples Wilcoxon Signed Rank Test.
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Table 3. YKL-40 levels (median, range) from baseline to 3 years from the diagnosis in patients with nonmetastatic RCC*
Nonmetastatic RCC
YKL-40 All (n=18) with relapse (n=6) without relapse (n=12)
Baseline 59.4 (16.1 – 285.9) 102.5 (16.1 – 123.9) 45.3 (21.6 – 285.9)
3 months 78.2 (20.8 – 226.3) 111.1 (20.8 – 171.4) 67.0 (21.5 – 226.3)
9 months 64.5 (25.3 – 329.6) 81.6 (25.3 – 329.6) 57.4 (26.1 – 209.3)
15 months 55.0 (27.7 – 209.8) 100.9 (35.3 – 209.8) 48.0 (27.7 – 202.2)
2 years 76.5 (17.6 – 494.9) 142.1 (18.3 – 494.9) 48.4 (17.6 – 275.1)
3 years 70.1 (23.6 – 833.0) 79.7 (47.1 – 217.9) 55.7 (23.6 – 833.0)
p 0.352 0.119 0.396
Change during follow-up were analysed by Related samples Friedman's Two-Way Analysis of Variance by Ranks.
*Complete series of blood samples from baseline to 3 years was available from 18 patients
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Table 4. Risk factors for survival in RCC patients
5-year survival 15-year survival
Age-adjusted univariate Multivariate Age-adjusted univariate Multivariate
N HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Age 82 1.01 (0.98-1.05) 1.03 (0.99-1.08) 1.02 (0.99-1.05) 1.02 (0.99-1.06)
Gender
Male 54 1.08 (0.50-1.37) 2.55 (1.07-6.08) 1.18 (0.62-2.24) 2.06 (0.996-4.25)
Female 28 1.00 1.00 1.00 1.00
Metastatic status
Nonmetastatic 61 1.00 1.00 1.00 1.00
Metastatic 21 12.3 (5.66-26.7) 19.2 (7.49-49.2) 7.59 (4.08-14.1) 11.8 (5.54-25.0)
Grade
1-2 54 1.00 1.00 1.00 1.00
3 28 2.93 (1.40-6.11) 2.51 (1.11-5.66) 2.01 (1.11-3.64) 1.89 (0.997-3.57)
YKL-40 tertiles
1 (≤55.0) 27 1.00 1.00 1.00 1.00
2 (55.1-120.0) 27 3.24 (1.01-10.4) 2.31 (0.70-7.62) 2.21 (0.95-5.14) 1.55 (0.66-3.64)
3 (>120.0) 28 5.26 (1.67-16.6) 3.84 (1.16-12.7) 4.34 (1.87-10.1) 3.19 (1.38-7.36)
Figures
Figure 1
Figure 1. Serum YKL-40 levels at the time of renal cell carcinoma diagnosis. Group
medians (black line), interquartile range (upper and lower border of the box) and ranges
(line bar) are presented in patients with nonmetastatic carcinoma with (n=31) or without
(n=30) relapse during the 15 years’ follow-up and in patients with metastatic disease at
the time of diagnosis (n=21). Differences between groups were calculated by Mann-
Whitney test. Outliers and extreme outliers are expressed as dots or stars.
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Figure 2
Figure 2. The cumulative 5-year (A; Log-Rank (Mantel-Cox) p = 0.008) and 15-year
(B; Log-Rank (Mantel-Cox) p < 0.001) survival curves of 82 patients with renal cell
carcinoma, divided into tertiles according to their baseline YKL-40 levels.
